Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.67 |
| ▸ | MMP3 | P08254 | 5/20 | 0.64 |
| ▸ | MMP2 | P08253 | 5/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.63 |
| ▸ | HRH2 | P25021 | 8/20 | 0.63 |
| ▸ | HRH1 | P35367 | 8/20 | 0.63 |
| ▸ | MMP1 | P03956 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16841044 | 1.00 | HDAC1 (0.67) | HDAC1HDAC2MMP3MMP2HRH3 | |
| SCHEMBL29444063 | 1.00 | HDAC1 (0.67) | HDAC1HDAC2MMP3MMP2HRH3 | |
| SCHEMBL26602050 | 0.98 | MMP3 (0.66) | HDAC1HDAC2MMP3MMP2HRH3 | |
| SCHEMBL7387284 | 0.94 | HRH3 (0.66) | HDAC1HDAC2MMP3MMP2HRH3 | |
| SCHEMBL7983991 | 0.94 | HRH3 (0.66) | HDAC1HDAC2MMP3MMP2HRH3 | |
| SCHEMBL5526919 | 0.94 | HRH3 (0.66) | HDAC1HDAC2MMP3MMP2HRH3 | |
| SCHEMBL12408526 | 0.94 | HRH3 (0.66) | HDAC1HDAC2MMP3MMP2HRH3 | |
| SCHEMBL5519875 | 0.91 | HRH3 (0.62) | HDAC1HDAC2MMP3MMP2HRH3 | |
| SCHEMBL25187982 | 0.91 | KDM4E (0.71) | HDAC1HDAC2MMP3MMP2HRH3 | |
| SCHEMBL25189699 | 0.91 | KDM4E (0.71) | HDAC1HDAC2MMP3MMP2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570334-B2 | Liquid crystal compound, liquid crystal composition, composite material with encapsulated liquid crystal, and liquid crystal display device using same | JNC CORPORATION (JP) | 2020-02-25 | — | — | US | disclosed |
| US-20180051210-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION, COMPOSITE MATERIAL WITH ENCAPSULATED LIQUID CRYSTAL, AND LIQUID CRYSTAL DISPLAY DEVICE USING SAME | JNC CORPORATION (JP) | 2018-02-22 | — | — | US | disclosed |
| WO-2016143634-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, COMPOSITE MATERIAL CONTAINING LIQUID CRYSTAL, AND LIQUID CRYSTAL DISPLAY ELEMENT USING LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION OR COMPOSITE MATERIAL CONTAINING LIQUID CRYSTAL | JNC株式会社 | 2016-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570334-B2 | Liquid crystal compound, liquid crystal composition, composite material with encapsulated liquid crystal, and liquid crystal display device using same | SOD1, SLC39A11, MTX1 | HDAC1 2319/4885HDAC2 4126/4885MMP3 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.